尤瑞克林联合阿替普酶治疗急性脑梗死患者的效果

Effects of urinary kallidinogenase combined with Alteplase on patients with acute cerebral infarction

目的:探讨尤瑞克林联合阿替普酶治疗急性脑梗死(ACI)患者的效果。方法:选取2020年1月至2021年6月该院收治的90例ACI患者进行前瞻性研究,按照随机数字表法分为观察组和对照组各45例。对照组采用阿替普酶溶栓治疗,观察组在对照组的基础上联合尤瑞克林治疗。比较两组疗效、治疗前后神经功能缺损[美国国立卫生研究院卒中量表(NIHSS)]评分、血液流变学指标[全血低切黏度、全血高切黏度、纤维蛋白原(FIB)、血浆黏度]水平及不良反应发生率。结果:观察组治疗总有效率为97.78%(44/45),高于对照组的80.00%(36/45),差异有统计学意义(P<0.05);观察组治疗后NIHSS评分及全血高切黏度、全血低切黏度、FIB水平、血浆黏度均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:尤瑞克林联合阿替普酶溶栓治疗ACI患者可提高治疗总有效率,改善神经功能及血液流变学指标水平,且安全性良好。

Objective:To explore effects of urinary kallidinogenase combined with Alteplase on patients with acute cerebral infarction.Methods:A prospective study was conducted on 90 patients with acute cerebral infarction admitted to this hospital from January 2020 to June 2021.They were divided into observation group and control group according to the random number table method,45 cases in each.The control group was treated with Alteplase thrombolytic therapy,while the observation group was treated with urinary kallidinogenase on the basis of that of the control group.The efficacy,the neurological deficit[national institutes of health stroke scale(NIHSS)],the hemorheology index levels[whole blood low shear viscosity,whole blood high shear viscosity,fibrinogen(FIB),plasma viscosity],and incidence of adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of treatment in the observation group was 97.78%(44/45),which was higher than 80.00%(36/45)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the NIHSS score,the whole blood high shear viscosity,the whole blood low shear viscosity,FIB level and the plasma viscosity in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Urinary kallidinogenase combined with Alteplase thrombolytic therapy for the acute cerebral infarction patients can improve the total effective rate of treatment,improve the levels of neurological function and hemorheology indexes,and has good safety.